Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 12, 2019

SELL
$3.94 - $9.7 $622 - $1,532
-158 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$8.6 - $11.26 $3,603 - $4,717
-419 Reduced 72.62%
158 $1,000
Q4 2017

Feb 22, 2018

SELL
$5.07 - $7.92 $583 - $910
-115 Reduced 16.62%
577 $4,000
Q3 2017

Oct 27, 2017

BUY
$5.4 - $8.47 $3,736 - $5,861
692
692 $5,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Cable Hill Partners, LLC Portfolio

Follow Cable Hill Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cable Hill Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cable Hill Partners, LLC with notifications on news.